Literature DB >> 30404036

Tofacitinib for the Treatment of Pyoderma Gangrenosum.

Bharati Kochar1, Neel Herfarth2, Céline Mamie2, Alexander A Navarini3, Michael Scharl2, Hans H Herfarth4.   

Abstract

Pyoderma gangrenosum (PG) is a difficult-to-treat inflammatory skin condition that affects inflammatory bowel disease (IBD) patients. There is no standardized approach for PG treatment.1 We report the results of 3 patients with Crohn's disease (CD) and refractory PG who had failed several therapies with biologics and were started on tofacitinib for severe inflammatory arthritis with resolution of their PG.
Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2018        PMID： 30404036     DOI： 10.1016/j.cgh.2018.10.047

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN： 1542-3565            Impact factor:   11.382


  10 in total

1.  Tofacitinib: A Jak of All Trades.

Authors:  Kristin E Burke; Ashwin N Ananthakrishnan
Journal:  Clin Gastroenterol Hepatol       Date:  2019-01-06       Impact factor: 11.382

Review 2.  Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease.

Authors:  Jurij Hanzel; Christopher Ma; Niels Vande Casteele; Reena Khanna; Vipul Jairath; Brian G Feagan
Journal:  Drugs       Date:  2021-01-05       Impact factor: 9.546

Review 3.  Maneuvering Clinical Pathways for Ulcerative Colitis.

Authors:  Christopher M Johnson; Catherine D Linzay; Themistocles Dassopoulos
Journal:  Curr Gastroenterol Rep       Date:  2019-09-05

4.  Dealing with Corticosteroid and High-Dose Cyclosporine Therapy in a Pyoderma Gangrenosum Patient Contracting a COVID-19 Infection.

Authors:  Marcella Ricardis May; Albert Rübben; Andrea Lennertz; Luk Vanstreels; Marike Leijs
Journal:  J Pers Med       Date:  2022-01-27

Review 5.  Emerging treatment options for extraintestinal manifestations in IBD.

Authors:  Thomas Greuter; Florian Rieder; Torsten Kucharzik; Laurent Peyrin-Biroulet; Alain M Schoepfer; David T Rubin; Stephan R Vavricka
Journal:  Gut       Date:  2020-08-26       Impact factor: 31.793

6.  Pyoderma Gangrenosum, Acne, and Hidradenitis Suppurativa Syndrome: A Case Report and Literature Review.

Authors:  Jundong Huang; Lemuel Shui-Lun Tsang; Wei Shi; Ji Li
Journal:  Front Med (Lausanne)       Date:  2022-03-24

Review 7.  Tofacitinib and newer JAK inhibitors in inflammatory bowel disease-where we are and where we are going.

Authors:  Eleanor Liu; Nasar Aslam; Gaurav Nigam; Jimmy K Limdi
Journal:  Drugs Context       Date:  2022-04-08

8.  Multiple Lesions at Different Stages of Pyoderma Gangrenosum in a Crohn's Disease Patient.

Authors:  Heng Zhang; Yifang Sun; Kun Li; Jianzhong Zhang; Xue Chen
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-08-09

Review 9.  Recent advances in managing and understanding pyoderma gangrenosum.

Authors:  Josh Fletcher; Raed Alhusayen; Afsaneh Alavi
Journal:  F1000Res       Date:  2019-12-12

10.  Recalcitrant and severe pyoderma gangrenosum attributable to levamisole-adulterated cocaine and treated successfully with oral tofacitinib.

Authors:  Andrew W Choi; Rachel Abuav; Susan M Rabizadeh; Rashad Ansari; Amanda F Marsch
Journal:  JAAD Case Rep       Date:  2020-07-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.